CalciMedica (CALC)

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

Dagens aktiekurs for CalciMedica, Inc. Common Stock (CALC) after-hours er 0,52 $, hvilket afspejler en bevægelse på -1,38 % after-hours siden markedet lukkede sidst . Virksomhedens markedsværdi er på 7,42 mio. $ med en daglig handelsvolumen på 448,80 t $ aktier. For investorer, der følger pristendenser, har CalciMedica, Inc. Common Stock-aktien ligget mellem 0,46 $ og 0,52 $ i dag. Den tidligere lukkepris var 0,52 $.

Er du klar til at komme i gang? Følg trinene nedenfor, eller læs vores guide om hvordan man køber CalciMedica aktier på Kraken med start fra $10.